Novocure Ltd (NVCR) Cash Flow Statement

The negative ratio arises because stock-based compensation of $17.5M and working capital inflows of $12.5M more than offset the reported net loss, meaning the positive operating cash figure is driven by accounting items rather than commercial profitability. Across the ten quarters, the ratio swings erratically between negative and above 1.0, which suggests cash conversion is unreliable as a quality signal and warrants further investigation into the timing of collections. Investors should monitor whether operating cash flow remains positive once stock compensation normalizes.

The recent positive free cash flow of $15.7M follows two quarters of deeply negative readings, so the trend appears directional rather than established. Because capital expenditure is consistently small at 2.8% to 7.6% of revenue, the swings in free cash flow are driven primarily by operating cash volatility rather than investment intensity. Sustained positive margins over several consecutive quarters would be needed before the improvement could be considered structural.

The absence of capital returns is consistent with a company still in a investment-phase, where cash is preserved to fund clinical programs and operations. This leaves the balance sheet as the primary buffer against the intermittent cash burn visible in the data. The retention strategy makes the durability of positive free cash flow more important, since no alternative deployment activity is currently competing for capital.